COMPLETE CITATION
Citation and identifiers
Jamadagni P, Dai Y, Liu Y, et al.. “Pharmaco-behavioral profiling identifies suppressors of autism gene-associated phenotypes in zebrafish.” Proceedings of the National Academy of Sciences. 123(12):e2518846123 · doi:10.1073/pnas.2518846123.
- PubMed ID
- 41838920 ↗
RESEARCH QUESTION
What high-throughput zebrafish pharmacology approach could inform future ASH1L model studies, despite ASH1L not being one of the genes tested?
The paper profiled 520 approved drugs across nine other autism-gene zebrafish mutants, making it methodological platform context rather than direct ASH1L treatment evidence.
INTERPRETATION BOUNDARY
Read the finding and limit together.
What this study supports
A Yale-led high-throughput resource profiled 520 FDA-approved drugs across nine large-effect autism-gene zebrafish mutants, extending a cross-gene behavioral and pharmacologic platform relevant to future model-based work.
What it cannot establish
ASH1L was not directly tested in this paper. Rescue validation centered on other gene models, so this is Yale platform context—not ASH1L treatment evidence.
OPEN THE STUDY